Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna Grenz Ray Therapy Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0231

    Grenz Ray Therapy for Skin Disorders

    Customize your policy alerts

    Sign up for Aetna Policy 0231 alerts

    Get alerted when Policy 0231 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's coverage stance on the use of Grenz ray (ultrasoft x-ray) therapy for dermatologic conditions and applies to Aetna members and treating providers.

    Policy Summary
    PayerAetna
    PolicyGrenz Ray Therapy for Skin Disorders
    Policy CodePolicy 0231
    Change TypeNo material change
    Effective DateApr 22, 1998
    Last ReviewMar 29, 2023
    Next Review DateFeb 22, 2024
    Key ActionDo not bill or seek coverage for Grenz ray therapy for dermatologic conditions because it is considered experimental/investigational.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    experimentalcoverage stance
    200 R/sessiontypical dose
    up to 5,000 Rmax cumulative
    17 listedreferences
    multiplemember languages

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Experimental and Investigational

    Covered when ALL of the following are met:

    Experimental/Investigational determination: Grenz ray therapy is considered experimental and investigational for the treatment of dermatologic conditions because there is inadequate evidence in the published peer-reviewed medical literature regarding its effectiveness.

    Policy statement - therapy not covered as medically necessary

    Radiation therapy is contraindicated for benign cutaneous lesions, particularly for dermatoses of the head and neck, because published observations report radiation-induced skin tumors and other neoplasms following such exposures. The policy notes that although Grenz ray therapy has been proposed for benign dermatoses unresponsive to conventional treatments, this use remains controversial in the peer-reviewed literature and carries documented safety concerns.

    Aetna considers Grenz ray therapy experimental and investigational for the treatment of dermatologic conditions due to inadequate evidence in the published peer‑reviewed medical literature regarding its effectiveness. As a result, Grenz ray therapy is not established as medically necessary for skin disorders and may be denied on that basis.

    Coding

    CPT/HCPCS codes mentionedmixed
    77401Radiation treatment delivery, superficial and/or ortho voltage, per day
    96900Actinotherapy (ultraviolet light)
    77499Unlisted code referenced for inappropriate indications
    ICD-10 examples listed (not all-inclusive)ICD-10
    A00.0 - B99.9Infectious and parasitic diseases
    C00.0 - D49.9Neoplasms
    L00 - L99Diseases of the skin and subcutaneous tissue
    Z51.0Encounter for antineoplastic radiation therapy

    Provider Actions & Billing

    Billing Rule

    Billing codes noted — CPT/HCPCS/ICD-10

    Billing/Coding: CPT/HCPCS/ICD-10 guidance is provided in the policy. CPT codes called out include 77401 (radiation treatment delivery, superficial and/or orthovoltage, per day), 96900 (actinotherapy - ultraviolet light), and when appropriate an unlisted radiation procedure code (e.g., 77499) may be required for Grenz ray therapy. ICD-10 groups listed as examples of diagnoses not covered for indications in this CPB include L00-L99 (diseases of the skin and subcutaneous tissue) and multiple other ranges noted in the policy. Providers should bill using the most appropriate code and may need to use an unlisted code when a specific Grenz ray code is not available.

    • CPT: 77401, 96900, 77499 (unlisted)
    • ICD-10 examples: L00-L99 and other ranges noted in policy
    Note

    Prior authorization — none specified

    Prior authorization: None specified in these policy sections. No prior authorization requirements are detailed for Grenz ray therapy in the provided document excerpts.

    Background

    Grenz rays are long‑wavelength, low‑energy (ultrasoft) x‑rays with very limited skin penetration, primarily absorbed within the most superficial layers of the skin (approximately the first ~2 mm). Historically they have been investigated for multiple inflammatory and benign skin disorders. Typical regimens described in the literature include weekly exposures (for example, around 200 R per session for a total of about 800–1,000 R), with the possibility of retreatment after several months and cumulative doses reported in some series up to about 5,000 R. Despite these historical uses, concerns about long‑term cancer risk and the limited quality of evidence supporting efficacy have led to their classification as an experimental therapy for dermatologic conditions.

    Definitions

    Grenz rays (definition and key facts)
    DefinitionGrenz rays are low-energy, long-wavelength (soft) x-rays with limited penetration that are almost entirely absorbed in the first ~2 mm of skin.
    Mechanism of effectExert predominant effect by reducing the number of dendritic lymphocytes (Langerhans cells) within the epidermis.
    Typical dosingTypical regimen: 200 rads (R) per session at weekly intervals for a total of 800–1,000 R.
    Retreatment and cumulative doseTreatment may be resumed after a 6-month rest, with total cumulative dose up to 5,000 R.
    Clinical applications investigatedInvestigated for multiple inflammatory and benign skin disorders (e.g., atopic dermatitis, psoriasis, lichen planus, seborrheic dermatitis, herpes simplex, hemangioma, lentigo maligna, Bowen's disease, patch stage mycosis fungoides, granuloma annulare, dyshidrosis, and persistent eczematous conditions).
    Policy Summary
    PayerAetna
    PolicyGrenz Ray Therapy for Skin Disorders
    Policy CodePolicy 0231
    Change TypeNo material change
    Effective DateApr 22, 1998
    Last ReviewMar 29, 2023
    Next Review DateFeb 22, 2024
    Key ActionDo not bill or seek coverage for Grenz ray therapy for dermatologic conditions because it is considered experimental/investigational.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & BillingBackgroundDefinitions
    Denial Risk

    Provider note & denial-risk

    Provider note: Grenz ray (borderline or ultrasoft x‑ray) has been proposed for benign dermatoses unresponsive to conventional therapy, but its use remains controversial. Published reports of radiation‑induced skin tumors indicate radiation therapy is contraindicated for benign cutaneous lesions, particularly for head and neck dermatoses. Aetna considers Grenz ray therapy experimental and investigational for dermatologic conditions due to inadequate evidence of effectiveness; claims may be denied as not medically necessary.

    • Grenz ray therapy considered experimental/investigational — denial risk for not medically necessary
    Note

    Step therapy — none specified

    Step therapy: No step therapy requirements are specified in these document sections.

    Note

    Policy review history and effective/next dates

    Policy review history: Effective date: 1998-04-22. Last review: 03/29/2023. Next scheduled review: 2024-02-22. Review history and definitions are available via the policy links.

    • Effective date: 1998-04-22
    • Last review: 2023-03-29
    • Next review: 2024-02-22
    • Links: Review History, Definitions
    Documentation Required

    Supplemental documentation links

    Supplemental documentation and resources are linked in the policy for provider reference, including Aetna glossary, program provisions, legal notices, plan disclosures, and other Aetna resources. External links are provided for convenience; Aetna is not responsible for content on external sites.

    • Glossary
    • Program Provisions
    • Legal Notices
    • Plan Disclosures
    • Aetna main resources and accessibility/legal pages
    Note

    Provider actions summary — none additional stated

    Provider actions summary: No additional provider actions are specified in these chunks beyond billing guidance, coding considerations, and awareness of the policy designation (experimental/investigational) which may result in claim denial.

    • No other provider actions stated in these sections